Trifluridine/Tipiracil Improves OS, PFS in Metastatic Gastric Cancer
Trifluridine plus tipiracil may be an effective treatment option for patients with heavily pretreated metastatic gastric cancer, according to presenters at ESMO 2018.
ESMO GI 2018
Real-World Study Reports PFS and OS in Metastatic CRC
A Merck-funded study examines survival data on patients with metastatic colorectal cancer; results were presented during ESMO 2018.
Benefit of Ramucirumab in Relapsed Hepatocellular Carcinoma Confirmed in Pooled Analysis
Ramucirumab prolonged progression-free survival (PFS) and overall survival (OS) in patients with relapsed/refractory hepatocellular carcinoma (HCC).
Pembrolizumab Did Not Improve PFS or OS Compared With Paclitaxel in Relapsed Gastric or Gastroesophageal Junction Cancer
Results from the KEYNOTE-061 were presented at ESMO World GI 2018.
Atezolizumab, Cobimetinib Combination Failed to Improve Survival Versus Regorafenib in Relapsed Colorectal Cancer
The IMblaze370 trial did not meet the primary endpoint.
Longer Overall Survival with FOLFIRINOX Versus Gemcitabine/nab-Paclitaxel in Pancreatic Cancer
Prior to this study, there were no conclusive data directly comparing these regimens.
Dendritic Cell Vaccine Plus Salvage Chemotherapy Active in Gastric Cancer
A recent trial evaluated the safety and efficacy of a DC vaccine combined with salvage chemotherapy.
Autophagy-Related Proteins May Be Prognostic Factors for CRC Survival With Chemotherapy
Researchers sought to determine if autophagy-related proteins are associated with survival among patients with CRC.
Real-World Regorafenib Outcomes Mirror Clinical Trial Results in Metastatic Colorectal Cancer
CORRECT and CONCUR trials demonstrated an improvement in OS for patients receiving regorafenib compared with placebo.
Identifying Potential Targets for Companion Diagnostic Tests Using Poly-Ligand Profiling
Researchers identified potential targets for a companion diagnostic tests using poly-ligand profiling (PLP) to determine which patients with locally advanced or metastatic pancreatic cancer may benefit from gemcitabine plus evofosfamide.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ESMO GI 2018
Loading... 
Loading...